Risk factors and the effect of belimumab on flares during glucocorticoid tapering in systemic lupus erythematosus: A multicentre ANSWER-SLE cohort study
Open Access
- 26 June 2026
- journal article
- Published by Oxford University Press (OUP) in Modern Rheumatology
- Vol. 36 (6) , 972-978
Abstract
Objectives: To identify the factors associated with flares after glucocorticoid (GC) reduction in systemic lupus erythematosus (SLE) and to determine whether belimumab (BLM) influences this risk. Methods: Using the ANSWER-SLE cohort, this retrospective, multicentre study enrolled 388 patients with a GC reduction from ≤5 mg/day. The primary outcome was the time to an overall flare (SLE Disease Activity Index 2000 [SLEDAI-2K] increase of ≥3 or a GC escalation). Multivariable Cox models identified factors associated with an overall flare. Propensity score-based matching weights were applied, and weighted Cox models assessed the association between BLM and flare risk. Results: During a 1-year follow-up, 133 overall flares occurred (1-year cumulative incidence 39.9%). A higher clinical SLEDAI (hazard ratio [HR] 1.10, 95% confidence interval [CI] 1.03–1.17), Systemic Lupus International Collaborating Clinics Damage Index (SDI) (HR 1.11, 95% CI 1.01–1.22), and GC dose reduction (HR 1.40, 95% CI 1.15–1.70) were associated with an increased overall flare risk. GC reductions of >1 mg were associated with flare (HR 2.53, 95% CI 1.54–4.15). In the weighted analyses, BLM was not associated with an overall flare (HR 0.83, 95% CI 0.51–1.34). Conclusions: In patients with SLE, carefully tapering GC doses from ≤5 mg/day according to disease activity and organ damage may be important, whereas BLM was not associated with a reduced flare risk.Keywords
This publication has 19 references indexed in Scilit:
- Factors and outcomes related to clinical inertia in systemic lupus erythematosus: a multicentre LUNA cohort studyRheumatology, 2025
- An observational study to identify causative factors for not using hydroxychloroquine in systemic lupus erythematosusScientific Reports, 2024
- Impact of low disease activity, remission, and complete remission on flares following tapering of corticosteroids and immunosuppressive therapy in patients with systemic lupus erythematous: a multinational cohort studyThe Lancet Rheumatology, 2023
- Real-World Effectiveness of Belimumab in Systemic Lupus Erythematosus: A Systematic Literature ReviewRheumatology and Therapy, 2022
- Low-dose glucocorticoids withdrawn in systemic lupus erythematosus: a desirable and attainable goalRheumatology, 2022
- 2019 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Systemic Lupus ErythematosusArthritis & Rheumatology, 2019
- Clinical SLEDAI-2K zero may be a pragmatic outcome measure in SLE studiesExpert Opinion on Biological Therapy, 2018
- SLICC damage index score in systemic lupus erythematosus patients and its associated factorsMedicine, 2018
- Combined Oral Contraceptives in Women with Systemic Lupus ErythematosusNew England Journal of Medicine, 2005
- The development and initial validation of the systemic lupus international collaborating clinics/American college of rheumatology damage index for systemic lupus erythematosusArthritis & Rheumatism, 1996